These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 17574889)
1. Concomitant, specific determination of growth hormone and pegvisomant in human serum. Ørskov H; Frystyk J; Nielsen C; Hansen AT; Weeke J; Jørgensen JO Growth Horm IGF Res; 2007 Oct; 17(5):431-4. PubMed ID: 17574889 [TBL] [Abstract][Full Text] [Related]
2. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant. Lüdecke DK; Crock PA; Bidlingmaier M; Schuppert F Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):509-12. PubMed ID: 23765756 [TBL] [Abstract][Full Text] [Related]
3. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600 [TBL] [Abstract][Full Text] [Related]
4. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly. Madsen M; Fisker S; Feldt-Rasmussen U; Andreassen M; Kristensen LØ; Ørskov H; Jørgensen JO Clin Endocrinol (Oxf); 2014 Jan; 80(1):92-100. PubMed ID: 23650996 [TBL] [Abstract][Full Text] [Related]
5. Detecting and solving the interference of pregnancy serum, in a GH immunometric assay. Dias ML; Vieira JG; Abucham J Growth Horm IGF Res; 2013; 23(1-2):13-8. PubMed ID: 23206731 [TBL] [Abstract][Full Text] [Related]
15. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994 [TBL] [Abstract][Full Text] [Related]
16. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Parkinson C; Burman P; Messig M; Trainer PJ J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131 [TBL] [Abstract][Full Text] [Related]
17. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148 [TBL] [Abstract][Full Text] [Related]
18. The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly. Paisley AN; Trainer PJ Horm Res; 2004; 62 Suppl 1():83-8. PubMed ID: 15761238 [TBL] [Abstract][Full Text] [Related]
19. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Droste M; Domberg J; Buchfelder M; Mann K; Schwanke A; Stalla G; Strasburger CJ Eur J Endocrinol; 2014 Jul; 171(1):59-68. PubMed ID: 24913198 [TBL] [Abstract][Full Text] [Related]
20. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]